RGD Reference Report - Proteome expression and carbonylation changes during trypanosoma cruzi infection and chagas disease in rats. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Proteome expression and carbonylation changes during trypanosoma cruzi infection and chagas disease in rats.

Authors: Wen, JJ  Garg, NJ 
Citation: Wen JJ and Garg NJ, Mol Cell Proteomics. 2011 Dec 22.
RGD ID: 6480538
Pubmed: PMID:22199233   (View Abstract at PubMed)
PMCID: PMC3322564   (View Article at PubMed Central)
DOI: DOI:10.1074/mcp.M111.010918   (Journal Full-text)

Inflammation and oxidative stress, elicited by Trypanosoma cruzi infection, are important pathologic events during progressive Chagasic cardiomyopathy. In this study, we infected Sprague Dawley rats with T. cruzi, and treated with phenyl-alpha-tert-butylnitrone (PBN-antioxidant) and/or benznidazole (BZ-anti-parasite). We employed two-dimensional gel electrophoresis (2D-GE)/mass spectrometry to investigate a) the plasma proteomic changes associated with infection and disease development, and b) the beneficial effects of PBN and BZ in controlling the disease-associated plasma profile. MALDI-TOF MS/MS analysis of differentially expressed (total 146) and oxidized (total 48) protein spots yielded 92 unique proteins. Our data showed that treatment with PBN and BZ restored the differential expression of 65% and 30% of the disease-associated proteins to normal level, respectively, and PBN prevented development of oxidative adducts on plasma proteins. Western blotting to detect dinitrophenyl-derivatized carbonyl-proteins revealed plasma proteins were maximally oxidized during acute infection. Functional and disease/disorder analyses allocated a majority of the differentially expressed and oxidized proteins into inflammation/immunity and lipid metabolism categories and to molecular pathways associated with heart disease (e.g., cardiac infarction, contractile dysfunction, hypertrophy, and hypertension) in chagasic rats, and to curative pathways (e.g. ROS scavenging capacity, immune regulation) in infected rats treated with PBN and/or BZ. We validated the 2D-GE results by Western blotting, and demonstrated that the disease-associated increased expression of gelsolin and vimentin and release of cardiac MYL2 in the plasma of chagasic rats was returned to control level by PBN/BZ treatment. Increased plasma levels of gelsolin, MYL2 and vimentin were directly correlated with the severity of cardiac disease in human chagasic patients. Together, these results demonstrate the plasma oxidative and inflammatory response profile, and plasma detection of cardiac proteins parallels the pathologic events contributing to Chagas disease development, and is of potential utility in diagnosing disease severity and designing suitable therapy for management of human chagasic patients.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Chagas disease severityIEP 6480538protein:increased expression:plasmaRGD 
Chagas disease  ISOVim (Rattus norvegicus)6480538; 6480538protein:increased expression:plasmaRGD 
Chagas disease severityISOVIM (Homo sapiens)6480538; 6480538protein:increased expression:plasmaRGD 
Chagas disease  IEP 6480538protein:increased expression:plasmaRGD 

Objects Annotated

Genes (Rattus norvegicus)
Vim  (vimentin)

Genes (Mus musculus)
Vim  (vimentin)

Genes (Homo sapiens)
VIM  (vimentin)


Additional Information